Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: magnifying endoscopy findings by Tong, DKH et al.
Title Helicobacter pylori-negative gastric mucosa-associatedlymphoid tissue lymphoma: magnifying endoscopy findings
Author(s) Law, TT; Tong, DKH; Wong, SWH; Chan, SY; Law, SYK
Citation Hong Kong Medical Journal, 2015, v. 21 n. 2, p. 183-186
Issued Date 2015
URL http://hdl.handle.net/10722/210826
Rights Creative Commons: Attribution 3.0 Hong Kong License
183Hong Kong Med J  ⎥  Volume 21 Number 2  ⎥  April 2015  ⎥  www.hkmj.org
A B S T R A C T 
Gastric mucosa–associated lymphoid tissue 
lymphoma is uncommon and most patients 
have an indolent clinical course. The clinical 
presentation and endoscopic findings can be 
subtle and diagnosis can be missed on white light 
endoscopy. Magnifying endoscopy may help identify 
the abnormal microstructural and microvascular 
patterns, and target biopsies can be performed. 
We describe herein the case of a 64-year-old 
woman with Helicobacter pylori–negative gastric 
mucosa–associated lymphoid tissue lymphoma 
diagnosed by screening magnification endoscopy. 
Helicobacter pylori–eradication therapy was given 
and she received biological therapy. She is in clinical 
remission after treatment. The use of magnification 
Helicobacter pylori–negative gastric mucosa–
associated lymphoid tissue lymphoma: 
magnifying endoscopy findings
Introduction
Primary extranodal low-grade B cell lymphoma of 
the mucosa-associated lymphoid tissue (MALToma) 
of stomach is uncommon. The clinical presentation 
is variable and there is no endoscopic hallmark. 
Magnifying endoscopy (ME) may help in the 
diagnosis of gastric MALToma. Herein we report 
the case of a patient who had gastric MALToma 
diagnosed by ME. 
Case report 
A 64-year-old woman had a history of cancer of 
alveolus that was in remission. She was considered 
at increased risk of developing squamous cell 
carcinoma of the upper aero-digestive tract; 
therefore, she was referred to us for endoscopic 
screening in May 2012. On white light endoscopy, 
a well-demarcated erythematous zone measuring 
3 cm in size was identified at the distal greater 
curvature of the stomach (Fig 1a). To further 
delineate this suspicious lesion, ME combined with 
narrow-band imaging (NBI) was used. Magnifying 
endoscopy was performed with a zoom endoscope 
(GIF-Q260Z; Olympus Hong Kong and China Ltd, 
China) which has a magnifying power of 80 times. 
The tip of the endoscope was mounted with a 
transparent cap for the purpose of focusing. Under 
ME in combination with NBI, a non-structural area, 
ie, complete or almost-complete disappearance of 
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gastric crypt epithelium and abnormal mucosal 
capillary pattern was identified (Fig 1a). Biopsy of 
the suspicious zone revealed atypical lymphoid 
cells with lymphoepithelial lesion formation. 
Immunohistochemical stains confirmed that the 
atypical lymphoid cells were positive for B cell 
marker CD20 (pan-B-cell marker: L26, Dako, UK), 
and negative for T cell markers CD3 and CD5 (Fig 
2). Helicobacter pylori was not found. These findings 
were consistent with gastric MALToma. Whole-
body positron-emission tomography scan did not 
show abnormal uptake in the stomach and the rest 
of body. 
 The patient was empirically treated with H
pylori–eradication therapy (esomeprazole 20 mg twice 
daily, amoxicillin 1 g twice daily, and clarithromycin 
500 mg twice daily for 1 week). She was then treated 
with four doses of rituximab (weekly for 4 weeks); 
this treatment was completed in June 2012. Repeated 
endoscopy and biopsy at 4 weeks after treatment 
showed a residual focus of MALToma. Radiotherapy 
(30 Gy) was subsequently given for improved local 
control in view of partial response to rituximab, 
which was completed in December 2012. Endoscopy 
performed 6 weeks after completion of radiotherapy 
showed complete response, ie, recovery of gastric pit 
pattern under ME (Fig 1b). 
Discussion
Gastric MALToma is uncommon and accounts 
CASE REPORT
endoscopy in gastric mucosa–associated lymphoid 
tissue lymphoma and its management are reviewed. 
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幽門螺桿菌陰性胃黏膜相關淋巴組織淋巴瘤： 
放大內鏡的結果
羅芷婷、唐琼雄、黃偉豪、陳小燕、羅英傑
胃黏膜相關淋巴組織淋巴瘤（MALToma）不常見，大多數患者的臨
床過程緩慢，其臨床表現和內鏡檢查結果亦很細微，普通白光內鏡檢
查很可能會錯過細微的胃黏膜異常病變。放大內鏡可幫助識別異常的
微觀結構和微血管形態，從而進行目標活檢。本文描述一名64歲女
性，經放大內鏡檢查後證實患有幽門螺桿菌陰性的MALToma。為患
者根除幽門螺桿菌並進行生物治療後見臨床緩解。本文綜述放大內鏡
對診斷MALToma的作用及MALToma的治療方法。
for 1% to 5% of all gastric cancers. Isaacson and 
Wright1 first reported a low-grade gastric lymphoma 
in 1983. Lymphoid tissue is absent in the normal 
gastric mucosa. Helicobacter pylori is believed to 
play a causative role in the development of gastric 
MALToma.2 Gastric lymphoid tissue is acquired in 
response to local infection by H pylori, and there is 
a strong association between H pylori infection and 
gastric MALToma. Approximately 90% of gastric 
MALTomas are H pylori positive. Pathogenesis of 
gastric MALToma is a multistep process; H pylori 
infection causes chronic gastritis, which leads to 
immunological reaction with formation of lymphoid 
follicles and, subsequently, to genetic abnormalities 
and malignant transformation. Eradication of H 
pylori may lead to remission in 50% to 90% of cases.3,4 
Most patients with gastric MALToma have an 
indolent clinical course; the 5-year overall survival 
after H pylori eradication has been reported to be 
82% to 96%.5,6   
 The presentation of MALToma is variable. 
Patients may present with non-specific symptoms 
such as epigastric pain, vomiting, and weight loss. 
Endoscopy with biopsy is diagnostic but there is no 
endoscopic hallmark. The endoscopic appearance is 
also non-specific. It is difficult to differentiate gastric 
MALToma from gastric erosion or gastritis on 
conventional white light endoscopy. Diagnosis can 
be easily missed if multiple biopsies are not taken. 
Narrow-band imaging allows enhanced visualisation 
FIG 1.  White light endoscopic images (upper) and magnified endoscopic images 
(lower)
(a) Magnified endoscopic image before treatment showing disappearance of the 
normal gastric pit pattern and appearance of irregular abnormal vessels (arrows). 
(b) Magnified endoscopic image after treatment showing recovery of gastric pits
FIG 2.  Histopathology before treatment
(a) The atypical lymphoid cells form lymphoepithelial lesions. 
They show pale cytoplasm and mildly irregular hyperchromatic 
nuclei (H&E; original magnification, x 40). (b) The atypical 
lymphoid cells are diffusely positive for B cell marker CD20
(a)
(b)
Before treatment After treatment
(a) (b)
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of microvascular and microsurface structures in 
the superficial part of the mucosa. The use of ME 
with NBI is useful for the diagnosis of early gastric 
cancer.7 Recently, retrospective studies have shown 
the characteristics of gastric MALToma on ME. Chiu 
et al8 reported abnormal spider-like vasculature and 
disappearance of gastric pits in nine patients with 
histological diagnoses of gastric MALToma, while 
Ono et al9 reported that non-structural areas with 
abnormal vessels were observed in 11 patients before 
treatment. The use of ME may help the endoscopist 
to take targeted biopsies from the abnormal areas.10 
 The histological criteria of gastric MALToma 
were established according to the World Health 
Organization criteria in 2001, which included 
(i) invasion of epithelial structures resulting in 
‘lymphoepithelial lesions’; (ii) small lymphocytes, 
marginal zone cells, and/or monocytoid B cells; (iii) 
infiltration of diffuse, perifollicular, interfollicular, or 
even follicular type due to colonisation of reactive 
follicles.11 
 Surgery has been replaced by medical therapy 
in the management of gastric MALToma.12 It is 
generally recommended that H pylori–eradication 
therapy be the first-line therapy for H pylori–
positive patients with localised gastric MALToma; 
eradication therapy should also be given to H pylori–
negative patients, as there may be false-negative 
results.13 About 60% to 90% of patients with gastric 
MALToma achieve complete response after H pylori 
eradication.13 The presence of atrophic-like mucosa 
is a characteristic finding after treatment of gastric 
MALToma. Reported post-treatment ME findings 
include recovery of gastric pits and resolution of 
abnormal vascular pattern.8 It was demonstrated 
that the disappearance of non-structural areas 
with abnormal vessels was related to pathological 
remission.10
 There is no consensus on treatment for those 
who fail to respond to eradication therapy. It is 
evident that patients with progressive disease or 
clinically evident relapse should undergo further 
treatment. Different treatment modalities include 
chemotherapy and radiotherapy. In a recently 
published multicentre cohort, high response rate 
to radiotherapy (94%) and chemotherapy (88%) 
was reported when used as second-line treatment 
in 82 non-responders and eight responders with 
relapse.14 Nine patients (out of 420 patients) showed 
transformation into diffuse large B cell lymphoma 
at a median follow-up period of 6 years.14 The 
management of patients with clinically partial 
remission is not well defined. A ‘watch and wait’ 
strategy has been advocated, and patients are 
followed up with interval endoscopies for evidence 
of progressive disease before considering oncological 
treatment.14 Rituximab, a chimeric antibody directed 
against CD20, is another therapeutic option. CD20 
is a B cell–specific antigen expressed abundantly by 
the neoplastic cells of MALToma. The response rate 
has been reported to be around 70% in small series.15 
 In summary, patients with gastric MALToma 
present with non-specific symptoms, and there is no 
endoscopic hallmark. Endoscopy and biopsy are the 
gold standard for diagnosis. Magnifying endoscopy 
findings in MALToma include abnormal vessel 
patterns and disappearance of gastric pits; however, 
these findings have not been confirmed by large-scale 
prospective studies. Helicobacter pylori eradication 
is the first-line treatment. While the majority of 
patients respond to eradication therapy, those who 
fail to respond and develop progressive disease 
require oncological treatment. The management 
of partial responders is uncertain. Surveillance 
endoscopy is recommended in the follow-up of 
patients with MALToma in order to detect relapse. 
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